Search clinical trials for: PD-1 knockout Engineered T cells

Total 251 results

The First Affiliated Hospital of Guangdong Pharmaceutical...
Guangzhou Anjie Biomedical Technology Co., Ltd.

Unknown

CAR T and PD-1 Knockout Engineered T Cells for Esophageal Cancer

Advanced Esophageal Cancer

China
Central South University

Recruiting

TACE Combined With PD-1 Knockout Engineered T Cell in Advanced Hepatocellular Carcinoma.

Advanced Hepatocellular Carcinoma

China
Mahmoud Ramadan mohamed Elkazzaz

Not yet recruiting

CRISPR/Cas9-modified Human T Cell ( PD-1and ACE2 Knockout Engineered T Cells ) for Inducing Long-term Immunity in COVID-19 Patients

COVID-19 Respiratory Infection
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Guangzhou Anjie Biomedical Technology Co., Ltd.

Completed

PD-1 Knockout Anti-MUC1 CAR-T Cells in the Treatment of Advanced Breast Cancer

Advanced Breast Cancer | Breast Neoplasm Malignant Female

China
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC

Non-small Cell Lung Cancer | Lung Neoplasm Malignant

China
Hangzhou Cancer Hospital
Anhui Kedgene Biotechnology Co.,Ltd

Completed

PD-1 Knockout Engineered T Cells for Advanced Esophageal Cancer

Esophageal Cancer

China
Third Military Medical University

Unknown

CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and Lymphoma

Burkitt Lymphoma | Acute Lymphoblastic Leukemia
The First Affiliated Hospital of Guangdong Pharmaceutical...
University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....

Unknown

Therapeutic Vaccine Plus PD-1 Knockout in Prostate Cancer Treatment

Prostate Cancer

China
Beijing YouAn Hospital
Beijing Gene Key Life Technology Co., Ltd.

Recruiting

Adoptive Autologous iNKT Cells for the Treatment of Progressed Hepatocellular Carcinoma Continuing on PD-1 Inhibitor Therapy

Hepatocellular Carcinoma

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multiple CAR-T Cell Therapy Targeting AML

Acute Myeloid Leukemia

China
Peking University
Shanghai Ming Ju Biotechnology Co., Ltd.

Recruiting

MAGE-A4-directed TCR-T in the Treatment Amongst Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China
Shenzhen Geno-Immune Medical Institute
The Seventh Affiliated Hospital of Sun Yat-sen University; Shenzhen Children... and other collaborators

Recruiting

4SCAR-CD44v6 T Cell Therapy Targeting Cancer

Cancers Which Are CD44v6 Positive

China
Shenzhen Geno-Immune Medical Institute

Recruiting

Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

4SCAR19U T Cells Targeting B Cell Malignancies

B Cell Malignancies

China
Shenzhen Geno-Immune Medical Institute
The Second Affiliated Hospital of Hainan Medical University; Beijing Jingdu...

Recruiting

Universal 4SCAR7U Targeting CD7-positive Malignancies

Acute Myeloid Leukemia | T-cell Acute Lymphoblastic Leukemia | T-cell Acute Lymphoblastic Lymphoma | NK Cell Lymphoma

China
Adaptimmune

Terminated

Long Term Follow up of Subjects Exposed to Genetically Engineered T Cell Receptors

Solid and Hematological Malignancies

United States, Canada
Changzhou No.2 People's Hospital

Not yet recruiting

γδ T-PD-1 Ab Cells in the Treatment of Advanced Solid Tumors

Advanced Solid Tumor
Shanghai Tongji Hospital, Tongji University School...

Unknown

Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Multiple Myeloma

China
Shenzhen Geno-Immune Medical Institute
Yunnan Cancer Hospital; Zhujiang Hospital, Southern Medical University, Guangzhou...

Unknown

Multi-CAR T Cell Therapy for Acute Myeloid Leukemia

Acute Myeloid Leukemia

China
Chinese PLA General Hospital

Unknown

CART-19 Immunotherapy in Mantle Cell Lymphoma

Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Non-hodgkin Lymphoma,B Cell

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Shanghai Cell Therapy Research Institute

Unknown

CTLA-4 and PD-1 Antibodies Expressing MUC1-CAR-T Cells for MUC1 Positive Advanced Solid Tumor

Advanced Solid Tumor

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART133

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Brain Tumor | Liver Cancer | Ovarian Tumor | Acute Myeloid and Lymphoid Leukemias

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19 (CART19)

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso

Pancreatic Cancer | Malignant Mesothelioma | Triple Negative Breast Cancer | Endometrial Cancer | Ovarian Tumor | Other Mesothelin Positive Tumors

China
Chinese PLA General Hospital

Unknown

Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Chinese PLA General Hospital

Completed

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | B-cell Chronic Lymphocytic... and other conditions

China
Sichuan University
Chengdu MedGenCell, Co., Ltd.

Completed

PD-1 Knockout Engineered T Cells for Metastatic Non-small Cell Lung Cancer

Metastatic Non-small Cell Lung Cancer

China
Chinese PLA General Hospital

Unknown

Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Hematopoietic/Lymphoid Cancer | Adult Acute Lymphoblastic Leukemia in Remission | Prolymphocytic Leukemia and other conditions

China
Henan Cancer Hospital
The Pregene (ShenZhen) Biotechnology Company, Ltd.

Unknown

Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

Relapsed Non Hodgkin Lymphoma

China
Sichuan University

Not yet recruiting

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients With CLDN18.2-positive Advanced Solid Tumors

Advanced Solid Tumor

China
Sichuan University

Recruiting

Dual-targeting VEGFR1 and PD-L1 CAR-T for Cancers Patients With Pleural or Peritoneal Metastases

Malignant Ascites | Malignant Peritoneal Effusion | Serous Cavity Metastatises

China
Sichuan University

Recruiting

Dual-targeting HER2 and PD-L1 CAR-T for Cancers With Pleural or Peritoneal Metastasis

Pleural Effusion, Malignant | Peritoneal Carcinoma Metastatic

China
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Breast Cancer | Pancreatic Adenocarcinoma | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Colorectal Carcinoma | Other Solid Tumors

United States
Dalian University

Unknown

Treatment of Non-small Cell Lung Cancer With Cytokine-induced Killer (CIK) Cells Blocked by PD-1 Antibody

Non-small Cell Lung Cancer
The Second Hospital of Nanjing Medical University

Unknown

Clinical Study on the Efficacy and Safety of c-Met/PD-L1 CAR-T Cell Injection in the Treatment of HCC

Primary Hepatocellular Carcinoma
Ningbo Cancer Hospital

Unknown

PD-1 Antibody Expressing CAR T Cells for Mesothelin Positive Advanced Malignancies

Advanced Cancer | Solid Tumor, Adult

China
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

Chimeric Antigen Receptor T-cells for The Treatment of AML Expressing CLL-1 Antigen

Acute Myeloid Leukemia

United States
Neogene Therapeutics, Inc.

Recruiting

A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation

Endometrial Cancer | Non-small Cell Lung Cancer | Pancreatic Ductal Adenocarcinoma | Colorectal Carcinoma | Solid Tumor, Adult | KRAS G12D

United States
Baylor College of Medicine
University of Texas, Southwestern Medical Center at Dallas

Completed

Evaluating the Use of RFT5-dgA to Deplete Alloreactive Cells Prior to Haploidentical Stem Cell Transplantation

Leukemia | Cancer

United States
Fred Hutchinson Cancer Center
SignalOne Bio, Inc.

Terminated

Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Anatomic Stage IV Breast Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Metastatic Malignant Solid Neoplasm | Metastatic Urothelial Carcinoma | Metastatic Triple-Negative Breast Carcinoma

United States
AlloVir
Baylor College of Medicine; The Methodist Hospital Research Institute; Center...

Completed

ARMS - Rapidly Generated Multivirus-Specific CTLs for Prophylaxis & Treatment of EBV, CMV, Adenovirus, HHV6 & BK Virus (ARMS)

Viral Infection

United States
Shanghai Cell Therapy Research Institute

Unknown

PD-1 Antibody Expressing mesoCAR-T Cells for Mesothelin Positive Advanced Solid Tumor (PAEMCMPAST)

Advanced Solid Tumor

China
Peking University
CARsgen Therapeutics Co., Ltd.

Completed

Chimeric Antigen Receptor T Cells Targeting claudin18.2 in Solid Tumors.

Advanced Solid Tumor

China
Medical College of Wisconsin
Children's Hospital and Health System Foundation, Wisconsin

Recruiting

CAR-20/19-T Cells in Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T)

Acute Lymphoblastic Leukemia | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, in Relapse | Acute Lymphoblastic Leukemia Recurrent | Acute Lymphoblastic Leukemia With Failed Remission | Acute Lymphoblastic Leukemia Not Having Achieved Remission

United States
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma

Hepatocellular Carcinoma
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Active, not recruiting

Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO)

Non-Hodgkin's Lymphoma | B-Cell ALL | B-Cell CLL

United States
Beijing 302 Hospital
Beijing GD Initiative Cell Therapy Technology Co., Ltd.; Chinese Academy of...

Not yet recruiting

Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody

Hepatocellular Carcinoma
Second Military Medical University

Unknown

Immunotherapy Using Pluripotent Killer-Programmed Cell Death 1 (PIK-PD-1) Cells for the Treatment of Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma

China
Peking University

Withdrawn

PD-1 Knockout Engineered T Cells for Metastatic Renal Cell Carcinoma.

Metastatic Renal Cell Carcinoma

Search clinical trials for: PD-1 knockout Engineered T cells

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations